Actively Recruiting
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
Led by University of Colorado, Denver · Updated on 2026-01-29
240
Participants Needed
2
Research Sites
421 weeks
Total Duration
On this page
Sponsors
U
University of Colorado, Denver
Lead Sponsor
J
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This protocol pertains specifically to the prospective lung squamous cell carcinoma pre-malignant lesion (PML) cohort that will form a primary study group for the Lung Pre-Cancer Atlas.
CONDITIONS
Official Title
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide signed and dated informed consent.
- Willingness to follow all study procedures and be available for the full study duration.
- Male or female aged over 18 years.
- Current or former smoker with over 20 pack-year smoking history.
- History of non-small cell lung cancer (stage I, II, or IIIA) with over 10 pack-year smoking history and no active disease at least 1 year after treatment.
- History of head and neck cancer (stage I, II, III, or IVA) with over 10 pack-year smoking history and no active disease at least 1 year after treatment.
- Able and willing to undergo at least three bronchoscopies.
- Prior bronchoscopic results showing either persistence or progression to high grade dysplasia at two or more airway sites, or endobronchial dysplasia at more than 3 airway sites, or high grade bronchial dysplasia (moderate or worse).
You will not qualify if you...
- Clinically apparent bleeding disorders.
- Life-threatening cardiac arrhythmias like ventricular tachycardia or multifocal premature ventricular contractions.
- Hypoxemia with less than 90% oxygen saturation even with supplemental oxygen before bronchoscopy.
- Active coronary artery disease including recent heart attack within 6 weeks, angina, poorly controlled heart failure, or other serious conditions preventing bronchoscopy.
- Acute bronchitis or pneumonia within 8 weeks, unless possibly due to lung cancer.
- Unable to provide informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Rocky Mountain Regional VAMC
Aurora, Colorado, United States, 80045
Actively Recruiting
2
UCHealth - Metro
Aurora, Colorado, United States, 80045
Actively Recruiting
Research Team
B
Brandi Kubala
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here